2013-09-24 13:00:17 - SADIF-Investment Analytics has applied its StockMarks™ stock-rating system to ISIS Pharmaceuticals, Inc. (ISIS) and produced a report, rating the company's attractiveness to long-term investors.
Ilhavo, Portugal - SADIF Investment Analytics, announces a new summary due diligence report covering ISIS Pharmaceuticals, Inc. (ISIS). The report uses SADIF's powerful StockMarks™ stock rating system and contains important analysis for any current or potential ISIS Pharmaceuticals, Inc. investor.
Report Summary: ISIS Pharmaceuticals, Inc. is a low quality company with a neutral outlook. ISIS Pharmaceuticals, Inc. has weak business growth and is run by mediocre management. The trend in ISIS Pharmaceuticals, Inc. fair value exchange rate against its closest rated-competitor, United Therapeutics Corporation, has been appreciating over the past 2 weeks. When compared to its closest competitor, ISIS Pharmaceuticals, Inc. shows similar undervaluation and is equally likely to underperform the market.
The report breaks down the Total StockMark into its three
components - business, management and price, performing an in-depth analysis of ISIS Pharmaceuticals, Inc. for long-term investors.
The report has been distributed to Thomson Reuters. It is available in Investext from multiple professional platforms including Thomson Research, Thomson ONE Banker, DIALOG/INTELLISCOPE, Thomson Gale, West Services, Advisen, Alacra-Datadownlink, Factiva, INTERNET SECURITIES and LEXIS/NEXIS or directly from SADIF-Investment Analytics at:
About SADIF-Investment Analytics:
SADIF-Investment Analytics is an independent investment research company covering sixteen different markets and over 20,000 companies. The StockMarks™ system is based on proven investment principles and is designed to drive long-term shareholder returns.